Two-thirds of primary GBM harbor amplifications and/or mutations of receptor tyrosine kinases (RTKs), most commonly the Epidermal Growth Factor Receptor (EGFR, 60%) and Platelet Derived Growth Factor Receptor α (PDGFRA, 10–15%)2. The gene discussed is EGFR; the disease is glioblastoma.